Volume 2, Issue 3 (July 2023)
Health Science Monitor 2023, 2(3): 180-204 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tourani M, Samavarchi Tehrani S, Movahedpour A, Rezaei Arablouydareh S, Maleksabet A, Savardashtaki A, et al . Design and evaluation of a multi-epitope vaccine for COVID-19: an in silico approach. Health Science Monitor 2023; 2 (3) :180-204
URL: http://hsm.umsu.ac.ir/article-1-119-en.html
URL: http://hsm.umsu.ac.ir/article-1-119-en.html
Mehdi Tourani * 
, Sadra Samavarchi Tehrani , Ahmad Movahedpour , Sahar Rezaei Arablouydareh , Amir Maleksabet , Amir Savardashtaki , Hojat Ghasemnejad‐Berenji , Mortaza Taheri-Anganeh
, Sadra Samavarchi Tehrani , Ahmad Movahedpour , Sahar Rezaei Arablouydareh , Amir Maleksabet , Amir Savardashtaki , Hojat Ghasemnejad‐Berenji , Mortaza Taheri-Anganeh
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
Abstract: (1342 Views)
Background & Aims: Corona virus disease-19 (COVID-19) is an evolving global disease which has burst into 2019. SARS-CoV-2 infects human cells through recognition of and binding to angiotensin converting enzyme-2 (ACE2) through the spike (S) glycoprotein. Spike is an immunogenic protein that can elicit immune responses. Multi-epitope vaccines are novel and efficient class of vaccines which are designed by linking the B and T cells. These epitopes stimulate both humoral and cellular immunity.
Materials & Methods: Based on bioinformatics online tools, appropriate epitopes of S protein were selected, linked together via suitable linkers, a TLR4 binding adjuvant was added, and a multi-epitope construct was constructed. The 3D model of the construct was predicted, refined, and validated. The antigenicity, allergenicity, solubility, and physico-chemical properties of vaccine were checked. The B cell conformational epitopes and IFN-γ inducing parts were detected. The adjuvant and TLR4 binding were evaluated by docking and protein-protein complex stability was assessed by elastic-mode analysis. The coding sequence of the vaccine construct was optimized and sub-cloned in expression vector through an in silico approach. Finally, the structure, energy, and stability of vaccine coding mRNA were evaluated.
Results: Ten continuous B cell epitopes, 9 T helper epitopes, and 8 CTL epitopes were chosen. The results showed that multi-epitope vaccine is a stable and soluble protein which can stimulate humoral and cellular immunity. Besides, the vaccine could stimulate immunity without inducing allergenicity in human body.
Conclusion: Finally, the vaccine can bind the TLR4 appropriately and can be expressed by a recombinant vector. The designed multi-epitope vaccine against COVID-19 could be considered as a suitable candidate for experimental studies.
Materials & Methods: Based on bioinformatics online tools, appropriate epitopes of S protein were selected, linked together via suitable linkers, a TLR4 binding adjuvant was added, and a multi-epitope construct was constructed. The 3D model of the construct was predicted, refined, and validated. The antigenicity, allergenicity, solubility, and physico-chemical properties of vaccine were checked. The B cell conformational epitopes and IFN-γ inducing parts were detected. The adjuvant and TLR4 binding were evaluated by docking and protein-protein complex stability was assessed by elastic-mode analysis. The coding sequence of the vaccine construct was optimized and sub-cloned in expression vector through an in silico approach. Finally, the structure, energy, and stability of vaccine coding mRNA were evaluated.
Results: Ten continuous B cell epitopes, 9 T helper epitopes, and 8 CTL epitopes were chosen. The results showed that multi-epitope vaccine is a stable and soluble protein which can stimulate humoral and cellular immunity. Besides, the vaccine could stimulate immunity without inducing allergenicity in human body.
Conclusion: Finally, the vaccine can bind the TLR4 appropriately and can be expressed by a recombinant vector. The designed multi-epitope vaccine against COVID-19 could be considered as a suitable candidate for experimental studies.
Type of Study: Research |
Subject:
Advanced Sciences and Technologies in Public Health
Received: 2023/05/3 | Accepted: 2023/06/21 | Published: 2023/07/19
Received: 2023/05/3 | Accepted: 2023/06/21 | Published: 2023/07/19
References
1. Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in Microbiology. 2020;11:298. [DOI] [PMID] [PMCID]
2. King AM, Lefkowitz EJ, Mushegian AR, Adams MJ, Dutilh BE, Gorbalenya AE, et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2018). Archives of virology. 2018;163(9):2601-31. [DOI] [PMID]
3. Khatami SH, Movahedpour A, Taheri-Anganeh M. Serological and RT-PCR diagnosis approaches for COVID-19. Health Science Monitor. 2022;1(1):24-31. [DOI]
4. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England journal of medicine. 2003;348(20):1967-76.
https://doi.org/10.1056/NEJMoa030747 [DOI] [PMID]
5. Azhar EI, Hui DS, Memish ZA, Drosten C, Zumla A. The Middle East Respiratory Syndrome (MERS). Infectious Disease Clinics. 2019;33(4):891-905. [DOI] [PMID] [PMCID]
6. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine. 2020. [Google Scholar]
7. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9.
https://doi.org/10.12932/AP-200220-0772 [DOI]
8. Ghelichi-Ghojogh M, Khezri R, Rezaei F, Aljalili S, Valizadeh R, Sadighpour T. Health inequality in COVID-19 vaccination coverage. Health Science Monitor. 2023;2(1):10-2. [DOI]
9. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. [DOI] [PMID] [PMCID]
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5 [DOI] [PMID]
11. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020;395(10224):565-74.
https://doi.org/10.1016/S0140-6736(20)30251-8 [DOI] [PMID]
12. Han Q, Lin Q, Jin S, You L. Coronavirus 2019-nCoV: A brief perspective from the front line. Journal of Infection. 2020;80(4):373-7. [DOI] [PMID] [PMCID]
13. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12(3):254. [DOI] [PMID] [PMCID]
14. Rahman MS, Hoque MN, Islam MR, Akter S, Rubayet-Ul-Alam A, Siddique MA, et al. Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: an in silico approach. BioRxiv. 2020. [DOI]
15. Srivastava S, Verma S, Kamthania M, Kaur R, Badyal RK, Saxena AK, et al. Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach. bioRxiv. 2020. [DOI]
16. Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020. [DOI]
17. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of medical virology. 2020;92(4):418-23. [DOI] [PMID] [PMCID]
18. Nourani A, Rahimkhoei V, Akbari A. Potential therapeutic drug candidates against SARS-CoV-2 (COVID‐19) through molecular docking: A review. Health Science Monitor. 2022;1(2):89-106. [DOI]
19. Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections. 2020;9(1):221-36. [DOI] [PMID] [PMCID]
20. Li F. Structure, function, and evolution of coronavirus spike proteins. Annual review of virology. 2016;3:237-61. [DOI] [PMID] [PMCID]
21. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS pathogens. 2018;14(8):e1007236. [DOI] [PMID] [PMCID]
22. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3. [DOI] [PMID] [PMCID]
23. Saha R, Prasad BV. In silico approach for designing of a multi-epitope based vaccine against novel Coronavirus (SARS-COV-2). bioRxiv. 2020. [DOI]
24. Behbahani M. In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus surface glycoprotein. bioRxiv. 2020. [DOI]
25. Commission GOoNH. General Office of National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for Novel Coronavirus Pneumonia. 2020. [DOI]
26. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4):372. [DOI] [PMID] [PMCID]
27. He X-J, Chen S-Y, Wu J-P, Yang L-R, Xu G. Highly efficient enzymatic synthesis of tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate with a mutant alcohol dehydrogenase of Lactobacillus kefir. Applied microbiology and biotechnology. 2015;99(21):8963-75. [DOI] [PMID]
28. Nosrati M, Mohabatkar H, Behbahani M. A novel multi-epitope vaccine for cross protection against hepatitis C virus (HCV): an immunoinformatics approach. Research in Molecular Medicine. 2017;5(1):17-26. [DOI]
29. Jain N, Shankar U, Majee P, Kumar A. Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes. BioRxiv. 2020. [DOI]
30. Yousefi T, Mir SM, Asadi J, Tourani M, Karimian A, Maniati M, et al. In silico analysis of non-synonymous single nucleotide polymorphism in a human KLK-2 gene associated with prostate cancer. Meta Gene. 2019;21:100578. [DOI]
31. Taheri-Anganeh M, Khatami SH, Jamali Z, Savardashtaki A, Ghasemi Y, Mostafavi-Pour Z. In silico analysis of suitable signal peptides for secretion of a recombinant alcohol dehydrogenase with a key role in atorvastatin enzymatic synthesis. Molecular biology research communications. 2019;8(1):17-26. [DOI]
32. Taheri-Anganeh M, Amiri A, Movahedpour A, Khatami SH, Ghasemi Y, Savardashtaki A, et al. In silico Evaluation of PLAC1-fliC As a Chimeric Vaccine against Breast Cancer. Iranian Biomedical Journal. 2020;24(3):173-82. [DOI] [PMID] [PMCID]
33. Vafadar A, Taheri-Anganeh M, Movahedpour A, Jamali Z, Irajie C, Ghasemi Y, et al. In Silico Design and Evaluation of scFv-CdtB as a Novel Immunotoxin for Breast Cancer Treatment. Int J Cancer Manag. 2020;13(1):e96094. [DOI]
34. Khatami SH, Taheri-Anganeh M, Arianfar F, Savardashtaki A, Sarkari B, Ghasemi Y, et al. Analyzing Signal Peptides for Secretory Production of Recombinant Diagnostic Antigen B8/1 from Echinococcus granulosus: An In silico Approach. Molecular Biology Research Communications. 2020:1-10. [DOI]
35. Asadi M, Gharibi S, Khatami SH, Shabaninejad Z, Kargar F, Yousefi F, et al. Analysis of Suitable Signal Peptides for Designing a Secretory Thermostable Cyanide Degrading Nitrilase: An in Silico Approach. Journal of Environmental Treatment Techniques. 2019;7(3):506-13. [Google Scholar]
36. Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, et al. Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach. BioRxiv. 2020. [DOI]
37. Shahid F, Ashfaq UA, Javaid A, Khalid H. Immunoinformatics guided rational design of a next generation multi epitope based peptide (MEBP) vaccine by exploring Zika virus proteome. Infection, Genetics and Evolution. 2020;80:104199. [DOI] [PMID]
38. Ikram A, Zaheer T, Awan FM, Obaid A, Naz A, Hanif R, et al. Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches. Scientific reports. 2018;8(1):1-14. [DOI] [PMID] [PMCID]
39. Hajighahramani N, Eslami M, Negahdaripour M, Ghoshoon MB, Dehshahri A, Erfani N, et al. Computational design of a chimeric epitope-based vaccine to protect against Staphylococcus aureus infections. Molecular and cellular probes. 2019;46:101414. [DOI] [PMID]
40. Hajighahramani N, Nezafat N, Eslami M, Negahdaripour M, Rahmatabadi SS, Ghasemi Y. Immunoinformatics analysis and in silico designing of a novel multi-epitope peptide vaccine against Staphylococcus aureus. Infection, Genetics and Evolution. 2017;48:83-94. [DOI] [PMID]
41. Negahdaripour M, Nezafat N, Eslami M, Ghoshoon MB, Shoolian E, Najafipour S, et al. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine. Infection, Genetics and Evolution. 2018;58:96-109. [DOI] [PMID]
42. Farhadi T, Nezafat N, Ghasemi Y, Karimi Z, Hemmati S, Erfani N. Designing of complex multi-epitope peptide vaccine based on omps of Klebsiella pneumoniae: an in silico approach. International Journal of Peptide Research and Therapeutics. 2015;21(3):325-41. [DOI]
43. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nature reviews Drug discovery. 2007;6(5):404-14. [DOI] [PMID]
44. Enjuanes L, Zuniga S, Castano-Rodriguez C, Gutierrez-Alvarez J, Canton J, Sola I. Molecular Basis of Coronavirus Virulence and Vaccine Development. Advances in virus research. 2016;96:245-86. [DOI] [PMID] [PMCID]
45. Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;92(5):495-500. [DOI] [PMID] [PMCID]
46. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic acids research. 2017;45(W1):W24-W9. [DOI] [PMID] [PMCID]
47. Saha S, Raghava GPS. Prediction of continuous B‐cell epitopes in an antigen using recurrent neural network. Proteins: Structure, Function, and Bioinformatics. 2006;65(1):40-8. [DOI] [PMID]
48. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC bioinformatics. 2007;8(1):424. [DOI] [PMID] [PMCID]
49. Bhasin M, Raghava G. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004;22(23-24):3195-204. [DOI] [PMID]
50. Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154(3):394-406. [DOI] [PMID] [PMCID]
51. Magnan CN, Zeller M, Kayala MA, Vigil A, Randall A, Felgner PL, et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010;26(23):2936-43. [DOI] [PMID] [PMCID]
52. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC bioinformatics. 2007;8(1):4. [DOI] [PMID] [PMCID]
53. Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v. 2-a server for in silico prediction of allergens. Journal of molecular modeling. 2014;20(6):2278. [DOI] [PMID]
54. Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics. 2014;30(6):846-51. [DOI] [PMID]
55. Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook: Springer; 2005. p. 571-607. [DOI]
56. Magnan CN, Randall A, Baldi P. SOLpro: accurate sequence-based prediction of protein solubility. Bioinformatics. 2009;25(17):2200-7. [DOI] [PMID]
57. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature protocols. 2010;5(4):725. [DOI] [PMID] [PMCID]
58. Shey RA, Ghogomu SM, Esoh KK, Nebangwa ND, Shintouo CM, Nongley NF, et al. In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases. Scientific reports. 2019;9(1):1-18. [DOI] [PMID] [PMCID]
59. Heo L, Park H, Seok C. GalaxyRefine: protein structure refinement driven by side-chain repacking. Nucleic acids research. 2013;41(W1):W384-W8. [DOI] [PMID] [PMCID]
60. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic acids research. 2007;35(suppl_2):W407-W10. [DOI] [PMID] [PMCID]
61. Lovell SC, Davis IW, Arendall III WB, De Bakker PI, Word JM, Prisant MG, et al. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Proteins: Structure, Function, and Bioinformatics. 2003;50(3):437-50. [DOI] [PMID]
62. Van Regenmortel MH. Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity. Methods. 1996;9(3):465-72. [DOI] [PMID]
63. Ponomarenko J, Bui H-H, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC bioinformatics. 2008;9(1):514. [DOI] [PMID] [PMCID]
64. López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón P. iMODS: internal coordinates normal mode analysis server. Nucleic acids research. 2014;42(W1):W271-W6. [DOI] [PMID] [PMCID]
65. Mauro VP. Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations. BioDrugs. 2018;32(1):69-81. [DOI] [PMID]
66. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Nature Publishing Group; 2020. [DOI] [PMID] [PMCID]
67. Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. International journal of biological sciences. 2020;16(10):1678. [DOI] [PMID] [PMCID]
68. Chatterjee S. Understanding the nature of variations in structural sequences coding for coronavirus spike, envelope, membrane and nucleocapsid proteins of sars-cov-2. Envelope, Membrane and Nucleocapsid Proteins of SARS-CoV-2 (March 28, 2020). 2020. [DOI]
69. Tehrani SS, Goodarzi G, Naghizadeh M, Khatami SH, Movahedpour A, Abbasi A, et al. In Silico Evaluation of Suitable Signal Peptides for Secretory Production of Recombinant Granulocyte Colony Stimulating Factor in Escherichia coli. Recent Patents on Biotechnology. 2020. [DOI] [PMID]
70. Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. EXCLI journal. 2020;19:410. [DOI] [PMID] [PMCID]
71. Hou Y-x, Peng C, Han Z-g, Zhou P, Chen J-g, Shi Z-l. Immunogenicity of the spike glycoprotein of Bat SARS-like coronavirus. Virologica Sinica. 2010;25(1):36-44. [DOI] [PMID] [PMCID]
72. Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs. Journal of Medical Virology. 2020. [DOI] [PMID] [PMCID]
73. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26(50):6338-43. [DOI] [PMID] [PMCID]
74. Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infectious diseases and therapy. 2020:1-20. [DOI] [PMID] [PMCID]
75. Tourani M, Karkhah A, Najafi A. Development of an epitope-based vaccine inhibiting immune cells rolling and migration against atherosclerosis using in silico approaches. Computational Biology and Chemistry. 2017;70:156-63. [DOI] [PMID]
76. Rahmani A, Baee M, Rostamtabar M, Karkhah A, Alizadeh S, Tourani M, et al. Development of a conserved chimeric vaccine based on helper T-cell and CTL epitopes for induction of strong immune response against Schistosoma mansoni using immunoinformatics approaches. International journal of biological macromolecules. 2019;141:125-36. [DOI] [PMID]
77. Deng H, Yu S, Guo Y, Gu L, Wang G, Ren Z, et al. Development of a multivalent enterovirus subunit vaccine based on immunoinformatic design principles for the prevention of HFMD. Vaccine. 2020. [DOI] [PMID]
78. Movahedpour A, Mostafavi-Pour Z, Sarkari B, Taheri-Anganeh M, Nezafat N, Savardashtaki A, et al. Designing a Multi-Epitope Antigen for Serodiagnosis of Strongyloides stercoralis Based on L3Nie. 01 and IgG Immunoreactive Epitopes. Avicenna Journal of Medical Biotechnology. 2022;14(2):114-24. [DOI] [PMID] [PMCID]
79. Gutiérrez AH, Loving C, Moise L, Terry FE, Brockmeier SL, Hughes HR, et al. In vivo validation of predicted and conserved T cell epitopes in a swine influenza model. PLoS One. 2016;11(7). [DOI] [PMID] [PMCID]
80. Chaudhuri D, Datta J, Majumder S, Giri K. In silico designing of peptide based vaccine for Hepatitis viruses using reverse vaccinology approach. Infection, Genetics and Evolution. 2020:104388. [DOI] [PMID]
81. Validi M, Karkhah A, Prajapati VK, Nouri HR. Immuno-informatics based approaches to design a novel multi epitope-based vaccine for immune response reinforcement against Leptospirosis. Molecular immunology. 2018;104:128-38. [DOI] [PMID]
82. Partovi Nasr M, Motalebi M, Zamani MR, Jourabchi E. In Silico Analysis and Expression of Osmotin-EAAAK-LTP Fused Protein. Journal of Genetic Resources. 2020;6(1):41-8. []
83. Khan M, Khan S, Ali A, Akbar H, Sayaf AM, Khan A, et al. Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. Scientific Reports. 2019;9(1):13321. [DOI] [PMID] [PMCID]
84. Rostamtabar M, Rahmani A, Baee M, Karkhah A, Prajapati VK, Ebrahimpour S, et al. Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitidis using comprehensive immunoinformatics approaches. Infection, Genetics and Evolution. 2019;75:103992. [DOI] [PMID]
85. Bazhan SI, Antonets DV, Karpenko LI, Oreshkova SF, Kaplina ON, Starostina EV, et al. In silico designed ebola virus T-cell multi-epitope DNA vaccine constructions are immunogenic in mice. Vaccines. 2019;7(2):34. [DOI] [PMID] [PMCID]
86. Jung S-Y, Kang KW, Lee E-Y, Seo D-W, Kim H-L, Kim H, et al. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018;36(24):3468-76. [DOI] [PMID] [PMCID]
87. Dauda A, Saul S, Kolo YS. Biocomputational Analysis of Chlamydia abortus Protein Sequence. 2017. [URL]
88. Rubin S, Qvit N. Cyclic Peptides for Protein− Protein Interaction Targets: Applications to Human Disease. Critical Reviews™ in Eukaryotic Gene Expression. 2016;26(3).
https://doi.org/10.1615/CritRevEukaryotGeneExpr.2016016525 [DOI] [PMID]
89. Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. Nature Reviews Immunology. 2019:1-10. [DOI] [PMID] [PMCID]
90. Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020. [DOI] [PMID] [PMCID]
91. Younan P, Ramanathan P, Graber J, Gusovsky F, Bukreyev A. The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge. mBio. 2017;8(2).
https://doi.org/10.1128/mBio.00226-17 [DOI] [PMID] [PMCID]
92. Modhiran N, Watterson D, Blumenthal A, Baxter AG, Young PR, Stacey KJ. Dengue virus NS1 protein activates immune cells via TLR4 but not TLR2 or TLR6. Immunology and cell biology. 2017;95(5):491-5. [DOI] [PMID]
93. Glasner DR, Ratnasiri K, Puerta-Guardo H, Espinosa DA, Beatty PR, Harris E. Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components. PLoS pathogens. 2017;13(11). [DOI] [PMID] [PMCID]
94. Marr N, Turvey SE. Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication. Innate immunity. 2012;18(6):856-65. [DOI] [PMID]
95. Olejnik J, Hume AJ, Mühlberger E. Toll-like receptor 4 in acute viral infection: Too much of a good thing. PLoS pathogens. 2018;14(12). [DOI] [PMID] [PMCID]
96. Sahin U, Holtkamp S, Tureci O, Kreiter S. Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency. Google Patents; 2019. [URL]
97. Bakhshi M, Ebrahimi F, Nazarian S, Zargan J. Computational analysis and gene cloning: design and preparation of a multi subunit vaccine consisting of EspA, Stx2B and Intimin antigens against enterohaemrrhagic Escherichia coli. 2018. [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
